The need for second-generation antihepatitis C virus testing in uremic patients on continuous ambulatory peritoneal dialysis.
OBJECTIVE
To assess the prevalence and clinical relevance of a hepatitis C virus (HCV) infection in continuous ambulatory peritoneal dialysis (CAPD) patients by first- (Ortho) and second-generation (Abbott and UBI) HCV antibody enzyme immunoassays.


METHODS
Thirty-two serum samples tested by first-generation HCV antibody enzyme immunoassays (EIA's) were reevaluated using two second-generation HCV antibody EIA's. Basic demographic data, history of blood transfusions, and duration of hemodialysis and CAPD were reviewed. Results were analyzed by chi square analysis, Wilcoxon rank sum, and the paired t-test.


METHODS
The medical college's affiliated teaching hospital.


RESULTS
The prevalence of the antibody anti-HCV increases with the duration of previous hemodialysis, but not with the duration of CAPD. The positive detection of anti-HCV by second-generation HCV antibody EIA's was higher than first-generation EIA's (25% and 34.4% vs 12.5%).


CONCLUSIONS
The prevalence and clinical relevance of HCV infection can be more accurately studied using the second-generation assays in uremic patients.
Ng
Y Y
YY
Department of Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China.
Lee
S D
SD
Wu
S C
SC
Liu
W T
WT
Chia
W L
WL
Huang
T P
TP
D000293:Adolescent; D000328:Adult; D000368:Aged; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000032:analysis*; D018937:Hepatitis C Antibodies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis; D014511:Uremia / Q000382:microbiology* / Q000628:therapy
D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies